Transplant-associated thrombotic microangiopathy: opening Pandora’s box

E. Gavriilaki, I. Sakellari, A. Anagnostopoulos, Robert A Brodsky

Research output: Contribution to journalArticle

Abstract

Transplant-associated thrombotic microangiopathy (TA-TMA) is an early complication of hematopoietic cell transplantation (HCT). A high mortality rate is documented in patients who are refractory to calcineurin inhibitor cessation. Estimates of TA-TMA prevalence vary significantly and are higher in allogeneic compared with autologous HCT. Furthermore, our understanding of the pathophysiology that is strongly related to diagnosis and treatment options is limited. Recent evidence has linked TA-TMA with atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative pathway of complement, opening the Pandora’s box in treatment options. As conventional treatment management is highly inefficient, detection of complement activation may allow for early recognition of patients who will benefit from complement inhibition. Preliminary clinical results showing successful eculizumab administration in children and adults with TA-TMA need to be carefully evaluated. Therefore, realizing the unmet needs of better understanding TA-TMA in this complex setting, we aimed to summarize current knowledge focusing on (1) critical evaluation of diagnostic criteria, (2) epidemiology and prognosis, (3) recent evidence of complement activation and endothelial damage and (4) treatment options.Bone Marrow Transplantation advance online publication, 13 March 2017; doi:10.1038/bmt.2017.39.

Original languageEnglish (US)
JournalBone Marrow Transplantation
DOIs
StateAccepted/In press - Mar 13 2017

Fingerprint

Thrombotic Microangiopathies
Transplants
Complement Activation
Cell Transplantation
Alternative Complement Pathway
Therapeutics
Bone Marrow Transplantation
Publications
Epidemiology
Mortality

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Transplant-associated thrombotic microangiopathy : opening Pandora’s box. / Gavriilaki, E.; Sakellari, I.; Anagnostopoulos, A.; Brodsky, Robert A.

In: Bone Marrow Transplantation, 13.03.2017.

Research output: Contribution to journalArticle

@article{79ad54f613f647839edc8c365d3e7009,
title = "Transplant-associated thrombotic microangiopathy: opening Pandora’s box",
abstract = "Transplant-associated thrombotic microangiopathy (TA-TMA) is an early complication of hematopoietic cell transplantation (HCT). A high mortality rate is documented in patients who are refractory to calcineurin inhibitor cessation. Estimates of TA-TMA prevalence vary significantly and are higher in allogeneic compared with autologous HCT. Furthermore, our understanding of the pathophysiology that is strongly related to diagnosis and treatment options is limited. Recent evidence has linked TA-TMA with atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative pathway of complement, opening the Pandora’s box in treatment options. As conventional treatment management is highly inefficient, detection of complement activation may allow for early recognition of patients who will benefit from complement inhibition. Preliminary clinical results showing successful eculizumab administration in children and adults with TA-TMA need to be carefully evaluated. Therefore, realizing the unmet needs of better understanding TA-TMA in this complex setting, we aimed to summarize current knowledge focusing on (1) critical evaluation of diagnostic criteria, (2) epidemiology and prognosis, (3) recent evidence of complement activation and endothelial damage and (4) treatment options.Bone Marrow Transplantation advance online publication, 13 March 2017; doi:10.1038/bmt.2017.39.",
author = "E. Gavriilaki and I. Sakellari and A. Anagnostopoulos and Brodsky, {Robert A}",
year = "2017",
month = "3",
day = "13",
doi = "10.1038/bmt.2017.39",
language = "English (US)",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Transplant-associated thrombotic microangiopathy

T2 - opening Pandora’s box

AU - Gavriilaki, E.

AU - Sakellari, I.

AU - Anagnostopoulos, A.

AU - Brodsky, Robert A

PY - 2017/3/13

Y1 - 2017/3/13

N2 - Transplant-associated thrombotic microangiopathy (TA-TMA) is an early complication of hematopoietic cell transplantation (HCT). A high mortality rate is documented in patients who are refractory to calcineurin inhibitor cessation. Estimates of TA-TMA prevalence vary significantly and are higher in allogeneic compared with autologous HCT. Furthermore, our understanding of the pathophysiology that is strongly related to diagnosis and treatment options is limited. Recent evidence has linked TA-TMA with atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative pathway of complement, opening the Pandora’s box in treatment options. As conventional treatment management is highly inefficient, detection of complement activation may allow for early recognition of patients who will benefit from complement inhibition. Preliminary clinical results showing successful eculizumab administration in children and adults with TA-TMA need to be carefully evaluated. Therefore, realizing the unmet needs of better understanding TA-TMA in this complex setting, we aimed to summarize current knowledge focusing on (1) critical evaluation of diagnostic criteria, (2) epidemiology and prognosis, (3) recent evidence of complement activation and endothelial damage and (4) treatment options.Bone Marrow Transplantation advance online publication, 13 March 2017; doi:10.1038/bmt.2017.39.

AB - Transplant-associated thrombotic microangiopathy (TA-TMA) is an early complication of hematopoietic cell transplantation (HCT). A high mortality rate is documented in patients who are refractory to calcineurin inhibitor cessation. Estimates of TA-TMA prevalence vary significantly and are higher in allogeneic compared with autologous HCT. Furthermore, our understanding of the pathophysiology that is strongly related to diagnosis and treatment options is limited. Recent evidence has linked TA-TMA with atypical hemolytic uremic syndrome, a disease of excessive activation of the alternative pathway of complement, opening the Pandora’s box in treatment options. As conventional treatment management is highly inefficient, detection of complement activation may allow for early recognition of patients who will benefit from complement inhibition. Preliminary clinical results showing successful eculizumab administration in children and adults with TA-TMA need to be carefully evaluated. Therefore, realizing the unmet needs of better understanding TA-TMA in this complex setting, we aimed to summarize current knowledge focusing on (1) critical evaluation of diagnostic criteria, (2) epidemiology and prognosis, (3) recent evidence of complement activation and endothelial damage and (4) treatment options.Bone Marrow Transplantation advance online publication, 13 March 2017; doi:10.1038/bmt.2017.39.

UR - http://www.scopus.com/inward/record.url?scp=85015070340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015070340&partnerID=8YFLogxK

U2 - 10.1038/bmt.2017.39

DO - 10.1038/bmt.2017.39

M3 - Article

C2 - 28287636

AN - SCOPUS:85015070340

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -